Nothing Special   »   [go: up one dir, main page]

Gompel et al., 2000 - Google Patents

Tibolone actions on normal and breast cancer cells

Gompel et al., 2000

View PDF
Document ID
3253729768713440590
Author
Gompel A
Siromachkova M
Lombet A
Kloosterboer H
Rostene W
et al.
Publication year
Publication venue
European Journal of Cancer

External Links

Snippet

Tibolone and its main derivatives were studied in an original model of cultures of normal human epithelial breast (HBE) cells on proliferation, differentation and apoptosis, the three mechanisms responsible for breast homeostasis. Tibolone and its Δ4 isomer were …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Similar Documents

Publication Publication Date Title
Gompel et al. Tibolone actions on normal and breast cancer cells
Sitruk-Ware Pharmacology of different progestogens: the special case of drospirenone
Stanczyk All progestins are not created equal
De Gooyer et al. Receptor profiling and endocrine interactions of tibolone
Sitruk-Ware Reprint of pharmacological profile of progestins
Sitruk-Ware Progestogens in hormonal replacement therapy: new molecules, risks, and benefits
Sitruk-Ware et al. The use of newer progestins for contraception
Schindler et al. Reprint of classification and pharmacology of progestins
Kandouz et al. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells
Canonico et al. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy
Baker Alternatives to oral estrogen replacement: transdermal patches, percutaneous gels, vaginal creams and rings, implants, and other methods of delivery
Schindler The “newer” progestogens and postmenopausal hormone therapy (HRT)
Wiegratz et al. Metabolic and clinical effects of progestogens
Gompel et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells
Jiang et al. The effects of progesterones on blood lipids in hormone replacement therapy
Crook et al. 7 Endocrine control of plasma lipoprotein metabolism: effects of gonadal steroids
Pasqualini Differential effects of progestins on breast tissue enzymes
Chetrite et al. Effect of nomegestrol acetate on estrone-sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells
Seeger et al. The effect of progesterone and synthetic progestins on serum-and estradiol-stimulated proliferation of human breast cancer cells
Pasqualini Progestins and breast cancer
Guerra et al. Progestins in combined contraceptives
Shields-Botella et al. An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells
Campagnoli et al. Differential effects of progestins on the circulating IGF-I system
Kuhl et al. Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications?
Thorneycroft Update on androgenicity